Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer

American Journal of Health-System Pharmacy

Volumn 61, Issue 3, 2004, Pages 261-266

  Davis, George A ^a   Rudy, Anita C ^b   Archer, Sanford M ^c   Wermeling, Daniel P ^d,e  

^a University of Kentucky   (United States)

^b Intranasal Technology Incorporated   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Division of Pharmacy Practice and Science   (United States)

^e University of Kentucky ^*

Author keywords

Absorption; Analgesics and antipyretics; Blood levels; Butorphanol tartrate; Dosage schedules; Drug administration routes; Phrmacokinetics; Sprays; Toxicity

Indexed keywords

BUTORPHANOL TARTRATE; BUTORPHANOL; NARCOTIC ANALGESIC AGENT;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIAPHORESIS; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DYSPNEA; EUPHORIA; EXTRASYSTOLE; FEMALE; FLUSHING; GAIT DISORDER; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; MAXIMUM ALLOWABLE CONCENTRATION; METERED DOSE INHALER; MULTIPLE DRUG DOSE; NASAL PRURITUS; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; TASTE DISORDER; URINARY HESITANCY; VOMITING; XEROSTOMIA; ADOLESCENT; ADULT; APPARATUS, EQUIPMENT AND SUPPLIES; BLOOD; DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; SOLUTION AND SOLUBILITY; TIME;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUTORPHANOL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; EQUIPMENT AND SUPPLIES; FEMALE; HUMANS; MALE; PHARMACEUTICAL SOLUTIONS; TIME FACTORS;

EID: 2942567759     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.3.261     Document Type: Article

References (18)

1. Gillis JC, Benfield P, Goa KL. Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs. 1995; 50:157-75.
2. Shyu WC, Pittman KA, Robinson D et al. Multiple-dose phase I study of transnasal butorphanol. Clin Pharmacol Ther. 1993; 54:34-41.
3. Shyu WC, Pittman KA, Robinson DS et al. The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. Eur J Clin Pharmacol. 1993; 45:559-62.
4. Shyu WC, Morgenthien EA, Barbhaiya RH. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment. Br J Clin Pharmacol. 1996; 41:397-402.
5. Vachharajani NN, Shyu WC, Garnett WR et al. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment. Clin Pharmacol Ther. 1996; 60:283-94.
6. Shyu WC, Morgenthien EA, Pittman KA et al. The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol. Eur J Clin Pharmacol. 1994; 47:57-60.
7. Shyu WC, Mayol RF, Pfeffer M et al. Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharm Drug Dispos. 1993; 14:371-9.
8. Vachharajani NN, Shyu WC, Greene DS et al. The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans. Biopharm Drug Dispos. 1997; 18:191-202.
9. Stadol NS (butorphanol tartrate) product information. Princeton, NJ: Bristol-Myers Squibb; 2002.
10. Fisher MA, Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology. 1997; 48:1156-60.
11. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982.
12. Davis GA, Rudy AC, Archer SM et al. Bioavailability of intranasal butorphanol using unit-dose sprayers in healthy volunteers. J Clin Pharmacol. 2002; 42:1058. Abstract.
13. Lemmer B. Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol. 1999; 51:887-90.
14. Washington N, McGlashan JA, Jackson SJ et al. The effect of nasal patency on the clearance of radiolabeled saline in healthy volunteers. Pharm Res. 2000; 17:733-6.
15. Gourlay GK, Plummer JL, Cherry DA. Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. Pain. 1995; 61:375-81.
16. Shiga T, Fujimura A, Tateishi T et al. The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects. Eur J Clin Pharmacol. 1993; 44:489-92.
17. Guentert TW. Time-dependence in benzodiazepine pharmacokinetics. Mechanisms and clinical significance. Clin. Pharmacokinet. 1984; 9:203-10.
18. Lemmer B. Chronopharmacology and its impact on antihypertensive treatment. Acta Physiol Pharmacol Bulg. 1999; 24:71-80.